Forum Topic News
  • Conversation: GSK sells eczema and psoriasis drug to Dermavant for £250m

    • July 13, 2018 1:05 PM BST
      • Post(s)

      GSK sells eczema and psoriasis drug to Dermavant for £250m

      GlaxoSmithKline’s new game plan for R&D under new R&D chief Hal Barron continues to take shape, and in the latest move the firm has sold off its lead immuno-inflammation disease asset.
      Psoriasis and atopic dermatitis (eczema) candidate tapinarof is being transferred to Roivant Sciences group company Dermavant in return for £150m upfront and another £100m in the offing if it meets development targets. The deal covers all markets except for China.
      Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), is being developed as a once-daily, topical treatment for the skin disorders that could provide an alternative to topical and oral steroids, which have side effects. In phase II trials the drug had a dose-dependent impact on plaque psoriasis lesions, and it is ready to move to phase III testing.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel